Vagal Nerve Stimulation Market is Estimated to grow at a Promising CAGR of 8.68% During Forecast 2017-2023
Market Overview:
The
global Vagal Nerve Stimulation Market
size is expected to balloon at 8.68% CAGR during the forecast
period (2017-2023). Rise in number of neurological disorders such as
epilepsy, depression, migraine, and others is one of the biggest drivers of the
market. According to the World Health Organization (WHO), neurological
disorders accounted for 4.5-11% of all diseases in low-income and mid-income
economies. High need for better treatment techniques and influx of capital into
research and development by pharmaceutical and biotechnology firms can create
opportunity of growth for the market.
Development
of novel technologies for epilepsy treatment and favorable reimbursement
policies proposed by governments in alliance with health coverage companies can
persuade patients for the treatment. Research for the management and treatment
of muscle function and organ disorders is likely to widen the scope of VNS
manufacturers in the market.
Paucity
of skilled surgeons and high costs of neurostimulation devices can pose a challenge
to the market growth. Side-effects of cardiac arrest and probability of
triggering a stroke can lead to hesitancy among doctors for prescribing the
treatment.
Competition Outlook:
·
LivaNova PLC
·
ElectroCore Medical LLC
·
EnteroMedics Inc
·
NeuroMetrix, Inc
·
Boston Scientific Corporation
·
Inspire Medical Systems
·
Cyberonics
·
ImThera Medical
Segmentation:
·
The global vagal nerve stimulation market is
segmented by product, application, and end-user.
·
By product, it is segmented into external VNS
devices and implantable VNS devices.
·
By application, it is segmented into
migraine, epilepsy, depression, and others.
·
By end-user, it is segmented into ambulatory
surgical centers, hospitals, and others.
Regional Analysis:
Asia
Pacific (APAC), the Americas, Europe, and the Middle East & Africa (MEA)
are major regions discussed in the global vagal nerve stimulation market.
The
Americas accounted for 43% market share in 2016. Rising government support for
research and development into neurological disorders, high healthcare spending,
and sophisticated healthcare infrastructure and framework for major
manufacturers to enter the region can bode well for the market growth. Presence
of large players as well as their increased capacity to invest in sufficient
amount of capital can encourage the market proliferation during the forecast
period.
Europe holds the second
position in the market standings due to availability of sufficient funds for
research and development and rise in government support. On the other hand, the
APAC region has latent potential for growth due to economies of China, South
Korea, Japan, and India. The increased healthcare budget of economies, large
patient pool, and development of neurostimulation technology are factors which
can boost the regional market growth
Comments
Post a Comment